We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$6.4B
AUM Growth
+$319M
Cap. Flow
-$190M
Cap. Flow %
-2.98%
Top 10 Hldgs %
23.07%
Holding
289
New
50
Increased
129
Reduced
80
Closed
21

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$95.2M
2
VRNA
Verona Pharma
VRNA
+$72.7M
3
GH icon
Guardant Health
GH
+$72.5M
4
CELC icon
Celcuity
CELC
+$63.7M
5
EVH icon
Evolent Health
EVH
+$53.2M

Sector Composition

Rank Sector Weight
1 Healthcare 42.37%
2 Industrials 17.69%
3 Technology 15.85%
4 Consumer Discretionary 6.94%
5 Utilities 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GH icon
1
Guardant Health
GH
$21.7B
$256M 4.01%
2,511,091
-810,247
-24% -$72.5M
XMTR icon
2
Xometry
XMTR
$5.39B
$175M 2.73%
2,936,126
-181,780
-6% -$10.2M
MIRM icon
3
Mirum Pharmaceuticals
MIRM
$5.94B
$165M 2.58%
2,093,582
-428,981
-17% -$30.8M
TT icon
4
Trane Technologies
TT
$98.8B
$157M 2.45%
403,274
+4,753
+1% +$1.97M
BBNX
5
Beta Bionics
BBNX
$887M
$152M 2.38%
4,994,728
+37,476
+0.8% +$1M
IRTC icon
6
iRhythm Holdings
IRTC
$3.96B
$123M 1.92%
692,486
+974
+0.1% +$173K
GEV icon
7
GE Vernova
GEV
$243B
$122M 1.91%
187,122
-5,576
-3% -$3.4M
LRCX icon
8
Lam Research
LRCX
$378B
$115M 1.79%
669,089
-235,606
-26% -$36.6M
SRRK icon
9
Scholar Rock
SRRK
$7.04B
$107M 1.67%
2,431,333
-368,123
-13% -$13.8M
AXSM icon
10
Axsome Therapeutics
AXSM
$10.4B
$104M 1.63%
571,226
-175,172
-23% -$24.5M
ARGX icon
11
argenx
ARGX
$64B
$102M 1.59%
121,221
-4,150
-3% -$3.55M
ODFL icon
12
Old Dominion Freight Line
ODFL
$41.2B
$95.8M 1.5%
610,644
+3,965
+0.7% +$568K
TRGP icon
13
Targa Resources
TRGP
$61.7B
$88.7M 1.39%
480,550
+104,931
+28% +$17.7M
TOST icon
14
Toast
TOST
$20.3B
$88.3M 1.38%
2,486,040
+4,465
+0.2% +$161K
COLL icon
15
Collegium Pharmaceutical
COLL
$786M
$86.9M 1.36%
1,876,239
-514,673
-22% -$21.5M
INSM icon
16
Insmed
INSM
$25.9B
$84.2M 1.31%
483,589
-521,518
-52% -$95.2M
ROP icon
17
Roper Technologies
ROP
$42.2B
$82M 1.28%
184,166
+2,260
+1% +$1.05M
VST icon
18
Vistra
VST
$46B
$78.7M 1.23%
487,636
+24,795
+5% +$4.52M
URI icon
19
United Rentals
URI
$64.1B
$77.7M 1.21%
95,940
+15,696
+20% +$13.6M
ASML icon
20
ASML
ASML
$651B
$71.5M 1.12%
66,820
+736
+1% +$768K
MTD icon
21
Mettler-Toledo International
MTD
$28B
$70.1M 1.1%
50,258
+815
+2% +$1.14M
NDAQ icon
22
Nasdaq
NDAQ
$55.5B
$68.8M 1.07%
707,048
+32,406
+5% +$2.91M
TMDX icon
23
Transmedics
TMDX
$3.07B
$66.7M 1.04%
548,267
+971
+0.2% +$122K
ETR icon
24
Entergy
ETR
$49.3B
$62.3M 0.97%
673,082
+22,039
+3% +$2.09M
MPWR icon
25
Monolithic Power Systems
MPWR
$61.7B
$62M 0.97%
68,373
+27,131
+66% +$26.1M

Similar funds

Eventide Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Eventide Asset Management held 289 positions worth $6.4B, up 5.3% from $6.08B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Eventide Asset Management's Q4 2025 filing shows 50 new, 129 increased, 80 reduced and 21 closed positions. Its largest new stake was Ionis Pharmaceuticals: 575,000 shares worth $45.5M. The largest sale was Insmed, an estimated $95.2M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Industrials and Technology.

  • Eventide Asset Management's largest Q4 2025 buy was Ionis Pharmaceuticals: 575,000 shares worth $45.5M.
  • Eventide Asset Management added most to Monolithic Power Systems in Q4 2025, an estimated $26.1M increase.
  • Eventide Asset Management's biggest Q4 2025 reduction was Insmed, cutting an estimated $95.2M.
  • Eventide Asset Management fully exited Verona Pharma in Q4 2025, selling an estimated $72.7M.
  • Eventide Asset Management's ten largest holdings make up 23% of its $6.4B portfolio in Q4 2025.
  • Eventide Asset Management opened 50 new positions and closed 21 in Q4 2025.
  • Eventide Asset Management's portfolio value rose 5.3% quarter-over-quarter to $6.4B.

Based on Eventide Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.